Ravi Mehrotra Joins Evercore ISI Research Team NEW YORK, January 7, 2019 – Evercore (NYSE:EVR) announced today that Ravi Mehrotra has joined Evercore ISI’s Healthcare Research team as a Senior Managing Director. Dr. Mehrotra joins Senior Analysts Umer Raffat and Josh Schimmer, enabling continued expansion of coverage of the Biopharma sector. Dr. Mehrotra brings over two decades of Healthcare equity research and investment banking experience to the Evercore ISI platform. He was most recently a partner at MTS Health Partners, and prior to that he spent 11 years at Credit Suisse as an Analyst and head of their global Biotechnology research team. During his time at Credit Suisse, Dr. Mehrotra was ranked the number one Biotechnology Analyst in both Institutional Investor and Extel surveys. Prior to Credit Suisse, Dr. Mehrotra was Head of European Biotechnology Equity Research at SG Cowen and a Pharmaceuticals Equity Analyst at Deutsche Bank. Marc Harris, Evercore ISI's Director of Research, said, "We are committed to providing our clients with the highest quality, differentiated, independent research analysis and advice. We are consistently investing in top tier talent to best serve our clients’ needs. Ravi brings exceptional experience to our Healthcare team with unique perspective and skills garnered from a distinctive career in healthcare financial services. This addition to an already strong team highlights our commitment to helping our clients in this strategically important sector." Dr. Mehrotra said, "I'm excited to join Evercore ISI and be a part of the premier Biopharma equity research franchise on the Street. I look forward to working alongside Josh and Umer." "Ravi is a very important addition to our Biotech effort, as we continue to expand our footprint and further serve our clients with independent and insightful company and thematic research,” said Josh Schimmer. “I’ve known Ravi for over a decade and am excited to have the opportunity to work collaboratively with him.” Umer Raffat said, "Ravi's vast experience interacting with C-level Biopharma leaders as both an equity analyst and investment banker over the years will be a tremendous asset in Evercore ISI’s Biopharma effort." Dr. Mehrotra holds a Bachelor of Science (Honors) and a Ph.D. in Biochemistry and Molecular Biology from Manchester University, U.K. About Evercore Evercore (NYSE: EVR) is a premier global independent investment banking advisory firm. We are dedicated to helping our clients achieve superior results through trusted independent and innovative advice on matters of strategic significance to boards of directors, management teams and shareholders, including mergers and acquisitions, strategic shareholder advisory, restructurings, and capital structure. Evercore also assists clients in raising public and private capital and delivers equity research and equity sales and agency trading execution, in addition to providing wealth and investment management services to high net worth and institutional investors. Founded in 1995, the Firm is headquartered in New York and maintains offices and affiliate offices in major financial centers in North America, Europe, South America, the Middle East and Asia. For more information, please visit www.evercore.com. Investor Contact: Jamie Easton Head of Investor Relations, Evercore +1.212.857.3100 Business Contact: Marc Harris Director of Research, Evercore ISI +1.212.446.5600 Media Contact: Dana Gorman The Abernathy MacGregor Group, for Evercore +1.212.371.5999 .